A Cardiomyopeptin Preparation Protects against Isoproterenol-Induced Chronic Heart Failure in Rats  

作　　者：Zumeng Xia Hoi Yan Leung Hoi Ling Siu Chung Wai Chan Kam Ming Ko Zumeng Xia;Hoi Yan Leung;Hoi Ling Siu;Chung Wai Chan;Kam Ming Ko(R&D Center, Infinitus China Limited, Guangzhou, China;Division of Life Science, Hong Kong University of Science & Technology, Hong Kong, China)

机构地区：[1]R&D Center, Infinitus China Limited, Guangzhou, China [2]Division of Life Science, Hong Kong University of Science & Technology, Hong Kong, China

出　　处：《Chinese Medicine》2023年第4期242-254,共13页中医(英文)

摘　　要：The present study investigated the effect of an herbal extract-supplemented cardiomyopeptin preparation (HECP), in the rat model of chronic heart failure. HECP pre-/co-treatment at a daily dose of 0.072 to 0.124 g/kg for 30 days protected against isoproterenol (ISO)-induced chronic myocardial damage in rats in a dose-dependent manner, with the extent of protection, as assessed by plasma cardiac troponin I level, being up to 76%. The cardioprotection afforded by HECP was associated with the enhancement of myocardial mitochondrial antioxidant status, amelioration of plasma parameters on cardiac dysfunction and hypertrophy, as well as an increase in myocardial endothelial nitric oxide synthase activity. Myocardial apoptotic and anti-apoptotic parameters were suppressed and stimulated, respectively. The cardioprotection afforded by HECP was accompanied by an increase in exercise capacity, an indirect functional index of the myocardium, in ISO-challenged rats. In conclusion, HECP may offer a promising prospect in preventing chronic heart failure in human subjects.The present study investigated the effect of an herbal extract-supplemented cardiomyopeptin preparation (HECP), in the rat model of chronic heart failure. HECP pre-/co-treatment at a daily dose of 0.072 to 0.124 g/kg for 30 days protected against isoproterenol (ISO)-induced chronic myocardial damage in rats in a dose-dependent manner, with the extent of protection, as assessed by plasma cardiac troponin I level, being up to 76%. The cardioprotection afforded by HECP was associated with the enhancement of myocardial mitochondrial antioxidant status, amelioration of plasma parameters on cardiac dysfunction and hypertrophy, as well as an increase in myocardial endothelial nitric oxide synthase activity. Myocardial apoptotic and anti-apoptotic parameters were suppressed and stimulated, respectively. The cardioprotection afforded by HECP was accompanied by an increase in exercise capacity, an indirect functional index of the myocardium, in ISO-challenged rats. In conclusion, HECP may offer a promising prospect in preventing chronic heart failure in human subjects.

关 键 词：Cardiomyopeptin Herbal Extract Chronic Heart Failure ISOPROTERENOL 

分 类 号：R54[医药卫生—心血管疾病]